Abstract:Circadian and sleep defects are well documented in Huntington's disease (HD). Modulation of the autophagy pathway has been shown to mitigate toxic effects of mutant Huntingtin (HTT) protein. However, it is not clear whether autophagy induction can also rescue circadian and sleep defects. Using a genetic approach, we expressed human mutant HTT protein in a subset of Drosophila circadian neurons and sleep center neurons. In this context, we examined the contribution of autophagy in mitigating toxicity caused by mutant HTT protein. We found that targeted overexpression of an autophagy gene, Atg8a in male flies, induces autophagy pathway and partially rescues several HTT-induced behavioral defects, including sleep fragmentation, a key hallmark of many neurodegenerative disorders. Using cellular markers and genetic approaches, we demonstrate that indeed the autophagy pathway is involved in behavioral rescue. Surprisingly, despite behavioral rescue and evidence for the involvement of the autophagy pathway, the large visible aggregates of mutant HTT protein were not eliminated. We show that the rescue in behavior is associated with increased mutant protein aggregation and possibly enhanced output from the targeted neurons, resulting in the strengthening of downstream circuits. Overall, our study suggests that, in the presence of mutant HTT protein, Atg8a induces autophagy and improves the functioning of circadian and sleep circuits. SIGNIFICANCE STATEMENT Defects in sleep and circadian rhythms are well documented in Huntington's disease. Recent literature suggests that circadian and sleep disturbances can exacerbate neurodegenerative phenotypes. Hence, identifying potential modifiers that can improve the functioning of these circuits could greatly improve disease management. We used a genetic approach to enhance cellular proteostasis and found that overexpression of a crucial autophagy gene, Atg8a , induces the autophagy pathway in the Drosophila circadian and sleep neurons and rescues sleep and activity rhythm. We demonstrate that the Atg8a improves synaptic function of these circuits by possibly enhancing the aggregation of the mutant protein in neurons. Further, our results suggest that differences in basal levels of protein homeostatic pathways is a factor that determines selective susceptibility of neurons.

Degradation Of Misfolded Proteins By Autophagy: Is It A Strategy For Huntington'S Disease Treatment?

Role of Chaperone-Mediated Autophagy in Degrading Huntingtons Disease-Associated Huntingtin Protein

Potential therapeutics targeting on autophagy for Huntington disease

Autophagy and Its Comprehensive Impact on ALS

Autophagy in Aging and Neurodegenerative Diseases: Implications for Pathogenesis and Therapy.

Proteasomal Dysfunction in Aging and Huntington Disease

Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease

Conformation-dependent Recognition of Mutant HTT (huntingtin) Proteins by Selective Autophagy

Autophagy regulates the processing of amino terminal huntingtin fragments.

mTOR inhibition in Q175 Huntington's disease model mice facilitates neuronal autophagy and mutant huntingtin clearance

Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments.

Targeting autophagy in neurodegenerative diseases: From molecular mechanisms to clinical therapeutics

Restoration of Sleep and Circadian Behavior by Autophagy Modulation in Huntington's Disease

Strategies to Investigate Ubiquitination in Huntington's Disease

Inhibition of HIPK3 by AST487 Ameliorates Mutant HTT-Induced Neurotoxicity and Apoptosis Via Enhanced Autophagy

Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates

Compartment-Dependent Degradation of Mutant Huntingtin Accounts for Its Preferential Accumulation in Neuronal Processes.

Compromised autophagy and neurodegenerative diseases

Molecular Strategies to Target Protein Aggregation in Huntington's Disease

Autophagy Modulation for Alzheimer's Disease Therapy.

Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson’s disease: potential therapeutic targets?